Nucleome’s advance in precision and scale of 3D genomics has solved the fundamental challenge of discovering molecular drivers of disease from human genetics Oxford, UK, 14 July 2026 – Nucleome Therapeutics (‘Nucleome’ or ‘the Company’) – a pioneering biotechnology company unlocking the therapeutic potential of the regulatory genome through its proprietary 3D genomics platform – […]
Ian Wells, former Global Chief Financial Officer of HOYA Vision Care, appointed CFO, bringing multi-billion-dollar P&L leadership and capital-markets discipline Tom West, who led Intersect ENT to its $1.1 billion acquisition by Medtronic and Nalu Medical to its $600 million acquisition by Boston Scientific, joins as an Independent Board Member Appointments build the financial and […]
Poolbeg Pharma Plc (AIM: POLB), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, is pleased to announce that it has raised £3.5 million (before expenses) pursuant to a placing of 58,333,328 new ordinary shares of 0.02 pence each in the capital of the Company (“Placing Shares”) with certain existing institutional and other investors (“Placing”). […]
Interim data remains on track for summer 2026 and partnering discussions continue to advance with multiple companies Highlights · First patient dosed in the POLB 001 TOPICAL clinical trial · Second site, University College London Hospital, activated with patient recruitment underway · Additional clinical sites expected to open imminently, supporting continued patient recruitment 13 July 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or […]
Sofinnova strengthens its growth strategy with a high-caliber London-based Partner Physician-scientist combining frontline clinical experience, health financing and policy expertise, and a proven track record in venture capital Over 20 years in drug development at Bristol Myers Squibb, Eli Lilly, and the Roche Venture Fund as well as in healthcare policy and financing PARIS, France […]
